HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Disorder of biliary tract — Clinical Guidelines

Overview

Neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD) is an autosomal recessive metabolic liver disease characterized by cholestasis, elevated liver enzymes, hyperammonemia, hypercitrullinemia, and fatty liver in infants, often presenting in the first few months of life 1 3 4 6.

Diagnosis

Clinical manifestations include cholestatic jaundice, failure to thrive, and elevated serum bile acids 4 6.

Biochemical markers: Elevated serum citrulline and bile acids, hypoproteinemia, and low vitamin K-dependent coagulation factors 1 4 6.

Genetic testing: Identification of mutations in the SLC25A13 gene via whole-exome sequencing (WES) or newborn screening 1 3 4.

Urinary sulfated bile acids assay can be a sensitive screening tool for cholestasis 8.

Differential diagnosis includes neonatal hepatitis, biliary atresia, and other genetic causes 7.

Management

First-line treatment: Nutritional therapy with lactose-free and medium-chain triglyceride (MCT) formula 1 4.

Supplementation: Fat-soluble vitamins to address deficiencies 1 4.

Ursodeoxycholic acid: Associated with improvement in biochemical measures of cholestasis 7.

Monitoring: Regular follow-up to assess liver function and nutritional status 1 4.

Special Populations

Pediatrics: Early diagnosis and timely management improve outcomes in infants with NICCD 1 4.

Comorbidities: Patients with severe liver impairment may exhibit coagulopathy and hypoalbuminemia, requiring careful monitoring of coagulation factors and iron status 5.

Key Recommendations

Early diagnosis through newborn screening and biochemical markers (elevated citrulline, bile acids) is crucial for improving outcomes (Evidence: Strong 1 4).

Initiate lactose-free and MCT formula as primary nutritional support in NICCD (Evidence: Strong 1 4).

Regular monitoring of liver function and nutritional status is essential for long-term management (Evidence: Moderate 4).

Consider urinalysis of sulfated bile acids for selective screening of neonatal cholestasis (Evidence: Moderate 8).

Aggressive nutritional support, including fat-soluble vitamins, should be provided to address deficiencies (Evidence: Moderate 7).

References

1 Inui A, Ko JS, Chongsrisawat V, Sibal A, Hardikar W, Chang MH et al.. Update on the diagnosis and management of neonatal intrahepatic cholestasis caused by citrin deficiency: Expert review on behalf of the Asian Pan-Pacific Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Journal of pediatric gastroenterology and nutrition 2024. link 2 Ranucci G, Della Corte C, Alberti D, Bondioni MP, Boroni G, Calvo PL et al.. Diagnostic approach to neonatal and infantile cholestasis: A position paper by the SIGENP liver disease working group. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2022. link 3 Lipiński P, Jurkiewicz D, Ciara E, Płoski R, Więcek S, Bogdańska A et al.. Neonatal cholestasis due to citrin deficiency: diagnostic pitfalls. Acta biochimica Polonica 2020. link 4 Ohura T, Kobayashi K, Tazawa Y, Abukawa D, Sakamoto O, Tsuchiya S et al.. Clinical pictures of 75 patients with neonatal intrahepatic cholestasis caused by citrin deficiency (NICCD). Journal of inherited metabolic disease 2007. link 5 Baptista-González H, Gutiérrez-Landeros F, Rosenfeld-Mann F, Trueba-Gómez R. Changes of coagulation inhibitors and fibrinolysis system in newborn infants with transitory neonatal cholestasis. Annals of hepatology 2004. link 6 Tazawa Y, Kobayashi K, Abukawa D, Nagata I, Maisawa S, Sumazaki R et al.. Clinical heterogeneity of neonatal intrahepatic cholestasis caused by citrin deficiency: case reports from 16 patients. Molecular genetics and metabolism 2004. link 7 McKiernan PJ. Neonatal cholestasis. Seminars in neonatology : SN 2002. link 8 Matsui A, Kasano Y, Yamauchi Y, Momoya T, Shimada T, Ishikawa T et al.. Direct enzymatic assay of urinary sulfated bile acids to replace serum bilirubin testing for selective screening of neonatal cholestasis. The Journal of pediatrics 1996. link70260-3) 9 Ginn-Pease ME, Pantalos D, King DR. TPN-associated hyperbilirubinemia: a common problem in newborn surgical patients. Journal of pediatric surgery 1985. link80236-0)

Disorder of biliary tract